Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Abstract

A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

What is claimed is:  
     
         1 . A selectively responsive composition comprising at least one substance including a bicyclo [3.2.1]octan in a double ring system having a basic chemical skeletal of a kaurene structure having the structural formula II: 
         
       
         
           
           
               
               
           
         
       
       or an analogue, derivative or metabolite thereof, wherein the substance responds only at an elevated plasma glucose concentrations.  
     
     
         2 . The composition according to  claim 1 , wherein the response of the substance is initiated by a plasma glucose concentration of 6 mmol/l or larger.  
     
     
         3 . The composition according to  claim 1 , wherein the substance is selected from the group consisting of steviol, isosteviol, glucosilsteviol, gymnemic acid, steviolbioside, steviosid Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E and Dulcoside A, their pharmaceutically acceptable analogues or their pharmaceutically acceptable derivates.  
     
     
         4 . The composition according to  claim 1 , wherein the substance is isolated from a plant source.  
     
     
         5 . A composition according to  claim 1 , in combination with at least one soy protein alone or in combination with at least one isoflavone.  
     
     
         6 . A dietary supplement comprising the composition according to  claim 1 .  
     
     
         7 . A dietary supplement comprising the composition according to  claim 5 .  
     
     
         8 . A medicament for a mammal comprising the selectively responsive composition of  claim 1  and which is responsive in the mammal only when the mammal's plasma glucose concentrations are elevated.  
     
     
         9 . The medicament according to  claim 8  for treating non-insulin dependent diabetes mellitus or metabolic syndrome in the mammal.  
     
     
         10 . The medicament according to  claim 8  for stimulating insulin production or for reducing glucagon concentrations in the blood of the mammal.  
     
     
         11 . The medicament according to  claim 8  for treating hypertension in the mammal.  
     
     
         12 . The medicament according to  claim 8 , wherein the medicament is an oral medicament and is self-regulating.  
     
     
         13 . A method of making a selectively responsive composition which comprises associating with a carrier a bicyclo [3.2.1]octan in a double ring system having a basic chemical skeletal of a kaurene structure having the structural formula II according to  claim 1  or an analogue, derivative or metabolite thereof, wherein the substance responds only at an elevated plasma glucose concentrations.  
     
     
         14 . The method according to  claim 13 , wherein the composition is made as a medicament for treating non-insulin dependent diabetes mellitus and/or metabolic syndrome in a mammal.  
     
     
         15 . The method according to  claim 13 , wherein the composition is made as a medicament for stimulating insulin production in a mammal.  
     
     
         16 . The method according to  claim 13 , wherein the composition is made as a medicament for reducing blood glucagon concentrations in a mammal.  
     
     
         17 . The method according to  claim 13 , wherein the composition is made as a medicament for treating hypertension in a mammal.  
     
     
         18 . The method according to  claim 13 , wherein the composition is made as a medicament for suppressing fasting plasma triglycerides in a mammal.  
     
     
         19 . The method according to  claim 13 , wherein the composition is made as a medicament for suppressing the total cholesterol level of the mammal.  
     
     
         20 . The method according to  claim 13 , wherein the composition is made as a dietary supplement.  
     
     
         21 . A method of treating non-insulin dependent diabetes mellitus and/or metabolic syndrome in a mammal in need of such treatment which comprises administering thereto a composition according to  claim 1 , wherein the substance is present in a therapeutically effective amount and becomes responsive only when the mammal experiences an elevated plasma glucose concentration.  
     
     
         22 . A method of treating hypertension in a mammal in need of such treatment which comprises administering thereto a composition according to  claim 1 , wherein the substance is present in a therapeutically effective amount and becomes responsive only when the mammal experiences an elevated plasma glucose concentration.  
     
     
         23 . A method of suppressing fasting plasma triglycerides in a mammal in need of such treatment which comprises administering thereto a composition according to  claim 1 , wherein the substance is present in a therapeutically effective amount and becomes responsive only when the mammal experiences an elevated plasma glucose concentration.  
     
     
         24 . A method of suppressing the total cholesterol level in a mammal in need of such treatment which comprises administering thereto a composition according to  claim 1 , wherein the substance is present in a therapeutically effective amount and becomes responsive only when the mammal experiences an elevated plasma glucose concentration.  
     
     
         25 . A method of suppressing appetite in a mammal in need of such treatment which comprises administering thereto a composition according to  claim 1 , wherein the substance is present in a therapeutically effective amount and becomes responsive only when the mammal experiences an elevated plasma glucose concentration.